HOME >> MEDICINE >> NEWS
Studies Look At Threshold Effect Of Cholesterol-Lowering "Statin" Drugs

DALLAS, April 21 -- Do individuals gain progressive benefits in heart attack protection as the drugs, called statins, take cholesterol levels to "new lows?" This is the topic of three reports and an editorial appearing in today's Circulation: Journal of the American Heart Association.

"An important question is how much additional benefit do individuals who have had a heart attack get from reducing their low-density lipoprotein, (LDL), or 'bad' cholesterol levels from low to very low levels, (below the recommended 100 milligrams/deciliter)? Is it considerable, small amounts or none?" asks Scott M. Grundy, M.D., Ph.D., who wrote an accompanying editorial in Circulation. He is director of the center for human nutrition at the University of Texas Southwestern Medical Center in Dallas.

In one report researchers found that the benefits of the popular statin drugs -- shown to sharply reduce heart attack risk in individuals with elevated blood levels of cholesterol -- taper off, indicating a "threshold" effect when LDL reaches 125 mg/dL, according to Frank M. Sacks, M.D., associate professor of medicine, and other researchers at Brigham and Women's Hospital and Harvard Medical School, Boston.

Another report in the same issue however suggested continued benefit down to a level of 100 mg/dL, although there was some lessening of benefit as LDL approached the lower levels.

Even though the data suggest that there may be attenuation in the benefit of cholesterol lowering below 125 mg/dL, Grundy stresses that these reports should not be taken as the final word on the issue. "For the present, the guidelines by the National Cholesterol Education Program (NCEP), endorsed by the American Heart Association, offer the most reliable basis for physicians' decisions regardless of the optimal lower limit for LDL cholesterol," says Grundy. A new statin trial, the Treating to New Target (TNT) study, should provide the answers concerning lower limit of benefit, but
'"/>

Contact: Carole Bullock
caroleb@amhrt.org
214-706-1279
American Heart Association
20-Apr-1998


Page: 1 2 3 4 5

Related medicine news :

1. Studies underscore genetic involvement in nicotine addiction & aggressive hostility
2. Studies address issues of risk and survival in rapidly increasing GI cancers
3. Studies examine coffee drinking and risk of liver and colorectal cancers
4. Studies reveal physicians attitudes on end-of-life care
5. Studies from the November issue of The Archives of Dermatology, a theme issue on facial rejuvenation
6. Studies link obesity to increased frequency of heartburn symptoms; greater risk of esophageal cancer
7. Studies demonstrate positive data in treatment of hepatitis C
8. Studies examine risk factors and potential consequences associated with prehypertension
9. Studies show ACTOS(R) (pioglitazone HCl) has positive effects on various components of dyslipidemia
10. Studies identify risk factors for colon cancer
11. Studies indicate healthy eating may affect cancer development, improve digestive system

Post Your Comments:
(Date:11/26/2014)... (PRWEB) November 26, 2014 The family ... $100,000 to the Mesothelioma Applied Research Foundation (Meso Foundation), ... Meso Foundation’s Patient Travel Grant Program . The ... is to create grant partnerships with organizations that can ... , Mr. Schulze is the founder and chairman emeritus ...
(Date:11/26/2014)... November 26, 2014 The American ... the Association’s new director of meetings and conferences. ... annual meeting, special events and conferences. , ... this post,” said AAA Executive Director Ed Liebow. ... enthusiasm and energy. She was recognized in January ...
(Date:11/26/2014)... Washington, DC (PRWEB) November 26, 2014 ... Inc.’s (AIS) independently published The AIS Report on Blue ... Inc. and WellPoint, Inc. on the varied strategies the ... costs and improve compliance with treatments for sleep apnea, ... The sleep disorder, because it’s linked to increased rates ...
(Date:11/26/2014)... Santa Rosa, California (PRWEB) November 26, 2014 ... be making never before seen reductions in prices of ... and Liposomal Vitamin D3 . Discounts ... only. , GI for Life’s proprietary ColoVite ... leading board-certified gastroenterologists to promote colon health. One easy-to-take ...
(Date:11/26/2014)... Anthropologists have identified concrete recommendations that ... Ebola, improve international support, and pave the way ... Africa. , The report, “Strengthening West African ... Insights,” will be made public during a press ... Fri., Dec. 5, 11 a.m., at the AAA ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... China, Nov. 26, 2014 China Nepstar Chain ... "Company"), a leading retail drugstore chain in China based ... its unaudited financial results for the third quarter ended September ... 30, 2014: , Same store sales increased by ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 million) ...
(Date:11/24/2014)... 24, 2014 Luoxis Diagnostics, Inc., a ... today announced the presentation of three clinical and ... a broadly applicable and robust research tool capable ... in response to injury, illness, or stress.  In ... with Luoxis, academic and pharmaceutical research partners, RedoxSYS ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
Cached News: